X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (32) 32
animals (21) 21
humans (21) 21
pharmacology & pharmacy (21) 21
polymer-bound doxorubicin (20) 20
drug delivery systems (13) 13
cancer (12) 12
doxorubicin (12) 12
phase-i (10) 10
mice (9) 9
anthracyclines (8) 8
chemotherapy (8) 8
doxorubicin - analogs & derivatives (8) 8
male (8) 8
doxorubicin - administration & dosage (7) 7
doxorubicin - pharmacokinetics (7) 7
doxorubicin - therapeutic use (7) 7
female (7) 7
neoplasms - drug therapy (7) 7
oncology (7) 7
acrylamides - chemistry (6) 6
antineoplastic agents - therapeutic use (6) 6
breast-cancer (6) 6
cell line, tumor (6) 6
chemistry, multidisciplinary (6) 6
doxorubicin - pharmacology (6) 6
drug carriers (6) 6
n-methacrylamide (6) 6
pharmacokinetics (6) 6
adriamycin (5) 5
antibiotics, antineoplastic - administration & dosage (5) 5
antibiotics, antineoplastic - pharmacokinetics (5) 5
antineoplastic agents - administration & dosage (5) 5
camptothecin (5) 5
cells (5) 5
drugs (5) 5
polymer-bound drugs (5) 5
polymers - chemistry (5) 5
vehicles (5) 5
antibiotics, antineoplastic - pharmacology (4) 4
antineoplastic agents - chemistry (4) 4
antitumor immunity (4) 4
doxorubicin - adverse effects (4) 4
drug delivery systems - methods (4) 4
drug targeting (4) 4
enzymatically degradable bonds (4) 4
hpma copolymers (4) 4
n-methacrylamide copolymers (4) 4
therapy (4) 4
acrylamides - administration & dosage (3) 3
acrylamides - therapeutic use (3) 3
antibiotics, antineoplastic - therapeutic use (3) 3
antitumor agent (3) 3
biochemical research methods (3) 3
biochemistry & molecular biology (3) 3
biochemistry, general (3) 3
biological-properties (3) 3
biotechnology & applied microbiology (3) 3
carcinoma, hepatocellular - drug therapy (3) 3
care and treatment (3) 3
copolymers (3) 3
drug carriers - chemistry (3) 3
hpma (3) 3
hydrogen-ion concentration (3) 3
in-vitro (3) 3
liver neoplasms, experimental - drug therapy (3) 3
lymphoma, t-cell - drug therapy (3) 3
macromolecular therapeutics (3) 3
mag-cpt (3) 3
mice, inbred c57bl (3) 3
middle aged (3) 3
molecular structure (3) 3
n- methacrylamide copolymers (3) 3
nanomedicine - methods (3) 3
ovarian-carcinoma cells (3) 3
pegylated liposomal doxorubicin (3) 3
permeability (3) 3
physicochemical characterization (3) 3
plasma (3) 3
polymer therapeutics (3) 3
polymers (3) 3
polymethacrylic acids - pharmacokinetics (3) 3
polymethacrylic acids - therapeutic use (3) 3
prodrug (3) 3
proteins (3) 3
rats (3) 3
research (3) 3
solid tumors (3) 3
tissue distribution (3) 3
tumor accumulation (3) 3
acrylamides - metabolism (2) 2
acrylamides - pharmacokinetics (2) 2
adult (2) 2
agents (2) 2
albumin (2) 2
analysis (2) 2
antibiotics, antineoplastic - adverse effects (2) 2
antibody (2) 2
anticancer drugs (2) 2
antimitotic agents (2) 2
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Anti-Cancer Drugs, ISSN 0959-4973, 02/2011, Volume 22, Issue 2, pp. 136 - 147
Galactosyl-terminated drug carriers are known to enhance drug accumulation in the liver, while possible accompanying hepatic toxicity is usually not clarified.... 
α,β-poly[(2-hydroxyethyl)-L-aspartamide] | doxorubicin | galactosyl | hepatotoxicity | hepatocellular carcinoma | POLYMER-BOUND DOXORUBICIN | PERFORMANCE | CARDIOTOXICITY | SYSTEMIC THERAPY | LACTOSAMINATED HUMAN ALBUMIN | alpha, beta-poly[(2-hydroxyethyl)-L-aspartamide] | PHARMACOKINETICS | ONCOLOGY | N-(2-HYDROXYPROPYL)METHACRYLAMIDE COPOLYMERS | ADRIAMYCIN | CONJUGATE | PHARMACOLOGY & PHARMACY | PHASE-I | Antibiotics, Antineoplastic - toxicity | Humans | Peptides - pharmacokinetics | Drug Carriers - administration & dosage | Drug Carriers - toxicity | Peptides - administration & dosage | Galactose - analogs & derivatives | Liver Neoplasms, Experimental - metabolism | Peptides - toxicity | Doxorubicin - analogs & derivatives | Female | Antibiotics, Antineoplastic - pharmacokinetics | Heart Diseases - chemically induced | Chemical and Drug Induced Liver Injury - etiology | Doxorubicin - administration & dosage | Galactose - pharmacokinetics | Doxorubicin - pharmacokinetics | Doxorubicin - toxicity | Mice, Inbred ICR | Antibiotics, Antineoplastic - administration & dosage | Animals | Liver Neoplasms, Experimental - drug therapy | Cell Line, Tumor | Galactose - toxicity | Drug Carriers - pharmacokinetics | Mice | HeLa Cells | Galactose - administration & dosage | Toxicity Tests | Drug Screening Assays, Antitumor | Index Medicus
Journal Article
Pharmaceutical Research, ISSN 0724-8741, 1/2010, Volume 27, Issue 1, pp. 200 - 208
In vivo efficacy and safety of HPMA-based copolymers armed with doxorubicin via a spacer containing pH-sensitive linkage that can be prepared within a broad... 
Biomedical Engineering | Biochemistry, general | immunomodulation | murine lymphoma | tumor resistance | Biomedicine | N -(2-hydroxypropyl)methacrylamide (HPMA) copolymer conjugate | Pharmacy | Medical Law | doxorubicin | Pharmacology/Toxicology | N-(2-hydroxypropyl) methacrylamide (HPMA) copolymer conjugate | Immunomodulation | Doxorubicin | Tumor resistance | Murine lymphoma | N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer conjugate | CANCER-CELL DEATH | POLYMER-BOUND DOXORUBICIN | IN-VITRO CYTOTOXICITY | CHEMISTRY, MULTIDISCIPLINARY | OVARIAN-CARCINOMA | MACROMOLECULAR THERAPEUTICS | PHYSICOCHEMICAL CHARACTERIZATION | N-(2-HYDROXYPROPYL)METHACRYLAMIDE COPOLYMERS | PHARMACOLOGY & PHARMACY | ANTITUMOR IMMUNITY | CONTROLLED ACTIVATION | BIOLOGICAL-PROPERTIES | Immunomodulation - drug effects | Polymethacrylic Acids - pharmacology | Antibiotics, Antineoplastic - pharmacology | Polymers - chemical synthesis | Doxorubicin - chemical synthesis | Male | Drug Carriers - chemical synthesis | Polymethacrylic Acids - chemical synthesis | Doxorubicin - pharmacokinetics | Drug Carriers - pharmacology | Xenograft Model Antitumor Assays | Animals | Doxorubicin - analogs & derivatives | Polymers - pharmacokinetics | Polymers - pharmacology | Polymethacrylic Acids - pharmacokinetics | Cell Line, Tumor | Cell Proliferation - drug effects | Drug Carriers - pharmacokinetics | Mice | Antibiotics, Antineoplastic - pharmacokinetics | Doxorubicin - pharmacology | Hydrogen-Ion Concentration | Anthracyclines | Non-Hodgkin's lymphomas | T cells | Analysis | Copolymers | Drug delivery systems | Lymphomas | Rodents | Pharmaceutical sciences | Index Medicus
Journal Article
Journal of Hepatology, ISSN 0168-8278, 10/2005, Volume 43, Issue 4, pp. 645 - 652
Journal Article
Advanced Drug Delivery Reviews, ISSN 0169-409X, 2009, Volume 61, Issue 13, pp. 1149 - 1158
This paper reviews an early clinical experience with anthracycline (epirubicin; Epi or doxorubicin; Dox) containing an -(2-hydroyxypropyl)methacrylamide... 
CRP | Cancer patients | NK cells | Tumor markers | Immunostimulation | LAK | Doxorubicin–HPMA–HuIg | Anthracycline antibiotics | HuIg | Epirubicin–HPMA–autologous IgG | Polymeric drug | HPMA | Epirubicin-HPMA-autologous IgG | Doxorubicin-HPMA-HuIg | C-REACTIVE PROTEIN | BONE-MARROW | POLYMER-BOUND DRUGS | PERIPHERAL-BLOOD | BREAST-CANCER | CARCINOMA CELL-LINE | CYCLOSPORINE-A | PHARMACOLOGY & PHARMACY | ANTITUMOR IMMUNITY | MULTIDRUG-RESISTANCE | PHASE-I | Doxorubicin - therapeutic use | Polymethacrylic Acids - adverse effects | Humans | Middle Aged | Antibiotics, Antineoplastic - adverse effects | Immunoglobulins, Intravenous - administration & dosage | Polymethacrylic Acids - therapeutic use | Drug Resistance, Neoplasm | Epirubicin - administration & dosage | Drug Carriers - chemistry | Drug Delivery Systems | Neoplasm Metastasis | Immunoglobulin G - immunology | Polymethacrylic Acids - administration & dosage | Doxorubicin - analogs & derivatives | Adult | Female | Doxorubicin - administration & dosage | Hemangiosarcoma - drug therapy | Immunologic Factors - administration & dosage | Immunologic Factors - immunology | Treatment Outcome | Breast Neoplasms - drug therapy | Immunoglobulin G - administration & dosage | Acrylamides - chemistry | Antibiotics, Antineoplastic - administration & dosage | Biomarkers, Tumor - blood | Animals | Antibiotics, Antineoplastic - therapeutic use | Epirubicin - therapeutic use | Quality of Life | Immunoglobulins, Intravenous - immunology | Doxorubicin - adverse effects | Epirubicin - adverse effects | Drugs | Care and treatment | Anthracyclines | Drug delivery systems | C-reactive protein | Immunoglobulin G | Metastasis | CEA (Oncology) | Cancer | Vehicles | Index Medicus | Anthracycline
Journal Article
Cancer Immunology, Immunotherapy, ISSN 0340-7004, 1/2007, Volume 56, Issue 1, pp. 35 - 47
Journal Article
Journal Article
Journal Article
Journal Article